Multiple Sclerosis Therapeutic Market Segmentation:
Route of Administration (Oral, Injectables)
In route of administration, oral segment is set to hold multiple sclerosis therapeutic market share of more than 58.5% by 2035. It is easier to monitor oral medications than injectable therapies, making a patient more compliant and convenient. The patients are allowed to take medication at home, in the absence of any medical supervision, thus enhancing their treatment process.
This convenience leads to adherence to the treatment routine, which is critical in chronic conditions including multiple sclerosis, as it demands a thorough treatment to manage symptoms, thereby, slowing disease progression. Moreover, continuous innovation in oral formulations, with improved safety profiles and efficacy in treating both relapsing and progressive MS, has further solidified their dominance in the market. For instance, in March 2019, the U.S. FDA approved Novartis’ Mayzent tablets to treat adults with relapsing forms of multiple sclerosis.
Distribution Channel (Hospital pharmacy, Retail pharmacy, Online Pharmacy)
In distribution channel, the hospital segment in multiple sclerosis therapeutic market is projected to witness a considerable growth during the forecast period, owing to their central role in diagnosing, managing, and treating the disease. Hospitals serve as key points for the administration of high-cost and complex therapies, including biologics, and monoclonal antibodies. These often need specialist supervision, and intravenous delivery in some cases. In addition, hospitals have necessary infrastructure for administering treatments that require refrigeration and specialized handling, making them a preferred channel for distributing these advanced therapies. Furthermore, hospitals tend to offer comprehensive care, including physical therapy, counseling, and access to multidisciplinary teams, positioning them as dominant players in the multiple sclerosis therapeutic market.
Our in-depth analysis of the global market includes the following segments:
|
Drug Class |
|
|
Route of Administration |
|
|
Distribution Channel |
|
